PubRank

A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)

Clinical Trial ID NCT02060188

PubWeight™ 23.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02060188

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2014 3.32
2 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
3 PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016 1.40
4 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
5 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
6 Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol 2015 0.90
7 From mice to humans: developments in cancer immunoediting. J Clin Invest 2015 0.90
8 Inflammatory networks underlying colorectal cancer. Nat Immunol 2016 0.88
9 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
10 Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) 2015 0.83
11 Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015 0.82
12 Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. Oncoimmunology 2015 0.81
13 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
14 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
15 The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med 2014 0.79
16 Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2016 0.78
17 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
18 Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016 0.78
19 Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointest Cancer Res 2014 0.75
20 The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med 2016 0.75
21 Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016 0.75
22 Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016 0.75
23 Colorectal clinical trials: what is on the horizon? Future Oncol 2016 0.75
24 The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. Cancers (Basel) 2015 0.75
25 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
26 Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016 0.75
Next 100